ALSO NOTED: Gentiae gains $16M in venture funds; Alexion kills pexelizumab program; Gentium gains Defibrotide rights;and much m

> Gentiae Clinical Research has gained $16 million in venture funds. The round was led by Bay City Capital. Report

> Alexion appears to have killed the development program for the anti-inflammatory pexelizumab due to discouraging Phase III data. Alexion had already released the data. Report

> Gentium has agreed to acquire the Italian marketing authorizations for Defibrotide and related trademarks, as well as certain other related assets, from Crinos S.p.A. for EUR 16 million in cash and other considerations. Release

> The FDA has approved the expanded use of Lilly's Byetta. Report

> Aerovance has announced positive top-line results from a Phase IIa trial of inhaled Aerovant in asthma patients. Release

> Tripos is selling its Discovery Research business in the U.K. to Provid Pharmaceuticals for $2 million. Report

And Finally... New research indicates that a moderate amount of alcohol can reduce the risk of heart attacks among men with high blood pressure. Article

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.